Skip to main content
NewslettersWatchlist

Inovio Pharma(INO-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low5.48
Day High5.75
Open:5.67
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
Motley Fool
Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcript
Barchart
5 Analyst-Approved Stocks Set to Join the Russell Microcap Index
Motley Fool
Better Buy: Inovio Pharmaceuticals vs. Novavax
Motley Fool
Inovio Pharmaceuticals (INO) Q1 2024 Earnings Call Transcript
Motley Fool
This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy?
Motley Fool
Inovio Pharmaceuticals (INO) Q4 2023 Earnings Call Transcript
Motley Fool
Inovio Pharmaceuticals (INO) Q3 2023 Earnings Call Transcript
PR Newswire
INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
Motley Fool
Inovio Pharmaceuticals (INO) Q2 2023 Earnings Call Transcript
PR Newswire
INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update
PR Newswire
INOVIO Reports Inducement Grants Under Inducement Plan
PR Newswire
INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023
GlobeNewswire
INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
PR Newswire
INOVIO to Present at the 2023 Jefferies Healthcare Conference
PR Newswire
INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
Motley Fool
Inovio Pharmaceuticals (INO) Q1 2023 Earnings Call Transcript
PR Newswire
INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights
PR Newswire
INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference
PR Newswire
INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023
Motley Fool
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
Motley Fool
Why Inovio Pharmaceuticals' Shares Jumped on Thursday

Profile

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.